Shaun D. Fontaine

Materials ScienceMedicineEngineeringBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft”.

Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft

Cancer Chemotherapy and Pharmacology(2019)10.1007/s00280-019-03903-5

N/A

0.515DataRank · unranked

30 citations

Byron Hann, Ralph Reid, Gary W. Ashley, Daniel V. Santi, Shaun D. Fontaine

Prostate-Specific Membrane Antigen Targeted Deep Tumor Penetration of Polymer Nanocarriers

ACS Applied Materials & Interfaces(2022)10.1021/acsami.2c15095

N/A

0.489DataRank · unranked

25 citations

Gary W. Ashley, Anil P. Bidkar, Suchi Dhrona, Cyril O.Y. Fong, Shaun D. Fontaine +7 more

Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma

Journal of Experimental & Clinical Cancer Research(2025)10.1186/s13046-025-03406-7

N/A

0.104DataRank · unranked

1 citations

Valentina Zanfagnin, Conway Xu, Erik Jessen, Yuanhang Liu, Chen Wang +17 more

PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM -Deficient Tumors and Potent Synergy With PARP Inhibitors

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-22-0217

N/A

0DataRank · unranked

11 citations

Shaun D. Fontaine, Morgan E. Diolaiti, Parth Desai, Rajesh Kumar, Nobuyuki Takahashi +9 more